Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug

US-based biotechnology company Kodiak Sciences has dosed the first subjects with diabetic retinopathy (DR) in its Phase III GLOW2 clinical trial of tarcocimab tedromer.

The randomised, multi-centre trial will assess the efficacy and safety of tarcocimab tedromer in treatment-naïve DR patients.